[Evidence Brief] The UK needs more systemic support for antibacterial innovation

The UK has played a leading role in international efforts to address antimicrobial resistance (AMR) through science policy and diplomacy. Domestically, a new reimbursement model that better recognises the value of new antibacterial drugs is being piloted, and there is much relevant research activity. However, areas of weakness remain that limit the UK’s contribution to antibacterial innovation. The UK’s capabilities in this vital field need long-term support through joined-up policies and a range of indicators need to be closely monitored to track the impact of these interventions.